R&D News

Onconic Therapeutics Makes KOSDAQ Debut, Trades Above IPO Price

Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, was officially listed on the KOSDAQ market on November 19. Established in 2020, Onconic Therapeutics is 46.28% owned by Jeil Pharmaceutical, making it the company’s largest shareholder. During its IPO process, Onconic attracted strong interest from institutional investors, with 842 domestic and international institutions participating in the demand forecast, resulting in a competitive ratio of 200 to 1. The IPO price was set at KRW 13...

Onconic Therapeutics2024-12-22

Ligachem Biosciences Announces First Patient Enrollment in Phase 1b Trial of CS5001 (ROR1-ADC, LCB71)

LigaChemBio2024-12-21

Daewoong Pharmaceutical’s Oral Drug for Liver Fibrosis 'DWP220' Selected as National New Drug Development Project

Daewoong Pharmaceutical announced on November 18 that its oral drug candidate "DWP220," designed to treat severe liver fibrosis, has been selected as a project for the second round of the 2024 National New Drug Development Project. This initiative is overseen by the Korea Drug Development Fund (KDDF). Liver fibrosis is a condition in which normal liver tissue is replaced with abnormal connective tissue due to repeated liver injury and inflammation, often caused by chronic fat accumulation. DW...

Daewoong Pharmaceutical2024-12-20

Dong-A ST Receives European Commission Approval for Stelara Biosimilar 'IMULDOSA'

Dong-A ST announced on November 18 that its Stelara (ustekinumab) biosimilar, "IMULDOSA" (project name DMB-3115), has received marketing authorization from the European Commission (EC). The EC approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP), an advisory body of the European Medicines Agency (EMA), recommended the approval of IMULDOSA in October. This milestone follows the U.S. Food and Drug Administration (FDA) approval granted in October, markin...

Dong-A ST2024-12-19

Inventage Lab Secures Patent for Semaglutide Microparticles and Manufacturing Method Using IVL-DrugFluidic Platform

Inventage Lab, a company specializing in long-acting injectable microspheres and lipid nanoparticle (LNP) manufacturing platforms, announced on November 17 that it has secured a patent for semaglutide microparticles and its proprietary manufacturing method. The newly registered patent is a foundational intellectual property for producing semaglutide microparticle formulations using the company's proprietary platform, IVL-DrugFluidic. According to Inventage Lab, this patent establishes a stron...

InventageLab 2024-12-17

Celltrion Acquires 100% Stake in Celltrion BioSolutions to Launch Full-Cycle CDMO Business

Celltrion announced on November 17 that it will acquire 2 million shares of Celltrion BioSolutions for KRW 10 billion (approximately USD 7.4 million), securing 100% ownership of the company. This acquisition marks a strategic step toward establishing a comprehensive Contract Development and Manufacturing Organization (CDMO) business. According to Celltrion, the decision to pursue a full-fledged CDMO business was made in September in response to growing global demand for biopharmaceuticals and...

Celltrion2024-12-17

EuBiologics Secures EAEU GMP Certification for V Plant, Paving the Way for Vaccine Exports to Eurasian Markets

eubiologics2024-12-16

Hanmi Pharmaceutical Partners with Bagel Labs to Develop Obesity Management Solution Combining Efpeglenatide and Digital Therapeutics

Hanmi Pharmaceutical2024-12-16

AbClon Receives NMPA Approval for Phase 2 Clinical Trial of AC101 for HER2-Positive Solid Tumors

AbClon announced on November 11 that it has received approval from China's National Medical Products Administration (NMPA) for a new Phase 2 clinical trial of AC101 (known as HLX22 under Henlius), a treatment being developed for various HER2-positive solid tumors. AC101 is a pipeline that was licensed to Henlius, a subsidiary of Fosun Pharma. The clinical trial for AC101 will be conducted in combination with either trastuzumab and chemotherapy or trastuzumab deruxtecan (T-DXd). The goal is to...

AbClon2024-12-12

Daewoong Pharmaceutical Joins Forces with Tionlab Therapeutics, Daehan Newpharm, and Dalim Biotech to Develop Once-Monthly Obesity Treatment

Daewoong Pharmaceutical announced on November 12 that it has signed a joint development agreement with Tionlab Therapeutics, Daehan Newpharm, and Dalim Biotech to create a long-acting obesity treatment injection that requires only once-monthly administration. The four companies will form a consortium to accelerate the development process by pooling their respective expertise in preclinical studies, clinical trials, drug development, and regulatory affairs. The new obesity treatment under deve...

Daewoong Pharmaceutical2024-12-12

Qurient Announces Clinical Plans for Adrixetinib (Q702) in AML at ASH 2024

QURIENT2024-12-11

Green Cross Acquires US Plasma Centers for KRW 138 Billion to Secure Stable Raw Material Supply for 'Aliglo'

Green Cross has announced its acquisition of ABO Holdings, a U.S.-based plasma center operator, for USD 102 million. This strategic move aims to secure a stable supply of raw materials for its blood plasma product, 'Aliglo' which has been recently introduced to the U.S. market. The acquisition was disclosed in a regulatory filing on November 11, with Green Cross confirming the purchase of all shares in ABO Holdings. The company cited the expansion of its U.S. plasma fractionation business as ...

GC corporation2024-12-11